Literature DB >> 15293076

Outcomes of ventilated COPD patients with nosocomial tracheobronchitis: a case-control study.

S Nseir1, C Di Pompeo, S Soubrier, P Delour, T Onimus, F Saulnier, A Durocher.   

Abstract

BACKGROUND: The aim of this study was to determine the impact of nosocomial tracheobronchitis (NTB) related to new bacteria on the outcome in patients with chronic obstructive pulmonary disease (COPD). PATIENTS AND METHODS: A prospective observational case-control study was conducted in medical COPD patients requiring intubation and mechanical ventilation for more than 48 hours. Patients with nosocomial pneumonia were excluded. Six matching criteria were used, including the duration of mechanical ventilation before NTB occurrence.
RESULTS: 81 matched case-control pairs were studied. Although the mortality rate was similar (40% vs 34%; p = 0.48), median duration of mechanical ventilation (20 vs 12 days; p = 0.015) and intensive care unit (ICU) stay (25 vs 18 days; p = 0.022) were higher in cases than in controls. NTB was independently associated with a longer than median period of mechanical ventilation among case and control patients (OR = 4.7 [95%CI = 2-10.9]; p < 0.001). In cases with appropriate antibiotic treatment compared with those who did not receive antibiotics, a shorter median duration of mechanical ventilation (12 vs 23 days; p = 0.006) and ICU stay (16 vs 29 days; p = 0.029) were observed.
CONCLUSION: NTB is associated with an increased duration of mechanical ventilation and ICU stays. Further studies are required to determine whether antibiotics could improve the outcome of patients with NTB.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15293076     DOI: 10.1007/s15010-004-3167-0

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  6 in total

1.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

Review 2.  Diagnosis of ventilator-associated respiratory infections (VARI): microbiologic clues for tracheobronchitis (VAT) and pneumonia (VAP).

Authors:  Donald E Craven; Jana Hudcova; Yuxiu Lei
Journal:  Clin Chest Med       Date:  2011-09       Impact factor: 2.878

Review 3.  Ventilator-Associated Tracheobronchitis: To Treat or Not to Treat?

Authors:  Despoina Koulenti; Kostoula Arvaniti; Mathew Judd; Natasha Lalos; Iona Tjoeng; Elena Xu; Apostolos Armaganidis; Jeffrey Lipman
Journal:  Antibiotics (Basel)       Date:  2020-01-31

4.  Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study.

Authors:  Saad Nseir; Raphaël Favory; Elsa Jozefowicz; Franck Decamps; Florent Dewavrin; Guillaume Brunin; Christophe Di Pompeo; Daniel Mathieu; Alain Durocher
Journal:  Crit Care       Date:  2008-05-02       Impact factor: 9.097

5.  Ventilator-associated tracheobronchitis: an update.

Authors:  Jorge Ibrain Figueira Salluh; Vicente Cés de Souza-Dantas; Ignacio Martin-Loeches; Thiago Costa Lisboa; Ligia Sarmet Cunha Farah Rabello; Nseir Saad; Pedro Póvoa
Journal:  Rev Bras Ter Intensiva       Date:  2019 Oct-Dec

6.  Contributing Factors to the Clinical and Economic Burden of Patients with Laboratory-Confirmed Carbapenem-Nonsusceptible Gram-Negative Respiratory Infections.

Authors:  Eilish McCann; Anita H Sung; Gang Ye; Latha Vankeepuram; Ying P Tabak
Journal:  Infect Drug Resist       Date:  2020-03-09       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.